Smith & Nephew (LON:SN) Downgraded to "Sector perform" Rating by Royal Bank Of Canada

Key Points

• Royal Bank of Canada downgraded Smith & Nephew to a "sector perform" rating and set a GBX 1,350 target, implying about a 16.48% upside from the company's current share price.
• Analyst consensus is cautious: two analysts rate the stock Buy and five Hold, with an average rating of "Hold" and an average target price of GBX 1,185.86.
• Shares opened at GBX 1,159, trading below the 50-day (GBX 1,236.09) and 200-day (GBX 1,258.20) moving averages; the company has a market cap of £12.71 billion and a PE ratio of 41.73.

Smith & Nephew (LON:SN - Get Free Report) was downgraded by equities researchers at Royal Bank Of Canada to a "sector perform" rating in a report released on Thursday,Digital Look reports. They currently have a GBX 1,350 target price on the stock. Royal Bank Of Canada's price objective would indicate a potential upside of 16.48% from the company's current price.

Other equities research analysts have also recently issued reports about the company. Berenberg Bank reiterated a "hold" rating and set a GBX 13 target price on shares of Smith & Nephew in a research note on Friday, May 1st. UBS Group reissued a "neutral" rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of GBX 1,185.86.

Smith & Nephew Trading Up 1.0%

Shares of LON:SN opened at GBX 1,159 on Thursday. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The company's fifty day moving average is GBX 1,236.09 and its two-hundred day moving average is GBX 1,258.20. The company has a market cap of £12.71 billion, a PE ratio of 41.73, a PEG ratio of 0.46 and a beta of 0.74.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.